Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation.

Fiche publication

Date publication

mai 2024

Journal

Experimental hematology & oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE CARVALHO BITTENCOURT Marcelo , Pr RUBIO Marie Thérèse , Dr D'AVENI-PINEY Maud , Dr DE ISLA Natalia

Tous les auteurs :
Notarantonio AB, Bertrand A, Piucco R, Fievet G, Sartelet H, Boulangé L, de Isla N, De Carvalho Bittencourt M, Hergalant S, Rubio MT, D'Aveni M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38734654

Résumé

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myeloid malignancies such as some acute myeloid leukemias (AML) and high-risk myelodysplastic syndromes (MDS). It aims to eradicate the malignant clone using immunocompetent donor cells (graft-versus-leukemia effect, GVL). Unfortunately, relapse is the primary cause of transplant failure mainly related on HLA loss or downregulation and upregulation of inhibitory ligands on blasts which result in donor immune effector dysfunctions.